Connect with us

Fertility

Virtual fertility clinic aims to challenge treatment experience

The world’s first virtual fertility clinic uses AI to maximise the chances of conception

Published

on

Source: unsplash.com

FemTech World meets Caroline Noublanche, co-founder and CEO of Apricity, the virtual clinic on a mission to change fertility care. 

Few people know that the world’s first baby to be conceived via in vitro fertilisation (IVF) was born in Manchester in 1978. Since then, IVF success rates have grown from 10 per cent to 50 per cent, according to a report from 2018.

Although the modern use of ultrasound imaging to harvest the eggs under a mild sedation has advanced the procedure, the complexity of the treatment has not changed a lot, says Caroline Noublanche.

“When you can’t conceive, you have to actually give up on the idea that the baby will be born naturally,” the CEO tells me.

“Even though IVF has existed for 40 years, it’s still a very painful process, organised around the constraints of the clinic and the doctor and emotionally, it’s a roller coaster of emotions. On average couples need three cycles, but in some cases they might need more or they might not succeed at all. So, IVF remains uncertain.”

Along with her co-founder, Andrew Berkley, Noublanche came up with the idea of reinventing fertility treatments, and launched Apricity in 2018. “Instead of having to go to a clinic 10 times on average during treatment, we wanted to arrange everything from the comfort of your home,” the CEO explains. “That includes video consultations, but also blood tests, scans, sperm analysis and drug delivery.

“The patients would only have to go to the clinic for two procedures: the collection and the embryo transfer. We also wanted to make the whole process a lot more digital so that the patients can have access to a fertility advisor who can answer their questions, arrange appointments and make sure that when they are short of drugs, they can get a top-up in time,” the co-founder continues.

“We also have a dedicated care team who supervise patients’ treatment and help with early diagnostic. Our two objectives [using the platform] are to deliver the best experience possible for patients and to maximise the chances to conceive through a mix of protocol adherence, treatment efficiency as well as a mix of algorithms and data-driven decisions which are there to help our patients.”

In a virtual clinic, doctor-patient communication is key and with a rise in digital health technology during the pandemic, more and more people are open to remote consultations. “When you have to go to the clinic, it can be quite intense,” Noublanche points out.

“We very much believe that delivering the best experience from the comfort of your home, where your partner can be present as well, can make a huge difference. There are 30 per cent mistakes today in treatments in traditional clinics, because it’s a lot of word of mouth. During a video consultation, however, one of our nurses is able to support the patients, so that they know the exact dose they need, when they need it and subsequently, have a much better product regimen.”

Apricity found that their doctors, nurses and advisors’ relationship with their patients is very different from the one they have in a traditional clinic. Seeing the couple – not just the woman undergoing the treatment – can enable doctors to also observe the dynamic of the two.

“I think COVID has really changed the perception of people on digital health as a whole,” says Noublanche. “Virtually, you’re gaining on aspects such as convenience and doctor-patient quality of the relationship itself. The goal of all of the data [collected] is to make sure that you don’t get a treatment with a one-size-fits-all type of approach.

“We use the data to inform our decisions and to make sure that we better personalise treatment. The customisation also comes from the emotional support we offer and which is extremely important in terms of mental health.”

A fertility predictor is also able to tell patients what their chances to conceive are when following a certain type of treatment. The CEO says that: “We try to show our patients the glass half full because it’s a moment when they tend to be a bit more fragile, but [the predictor] also tells them black on white what their chances are.

“We are also transparent about the costs from the very beginning. What we don’t want is starting a treatment you would think would cost £4,000 and then find out that you have to pay another £1,000 for drugs or additional consolations. Yes, sometimes we lose and sometimes we gain, but we always want to be transparent. I think that’s very important.”

Caroline says the team have big plans for the future, focusing on the expansion of the company beyond the UK. “Our mission is to become the queen of Europe in fertility treatment,” she proudly tells me.

“We are planning to be present in Italy, Germany and in other European countries and continue to deliver the same quality of care and same attention to patients.”

She adds that: “At the moment we already outperform the national average of 61 per cent, so we have amazing success rates. We do everything with a data-driven approach and tech to provide efficiency. What we want is to continue to increase our success rates.

The CEO says that the feedback they receive is what keeps Apricity going and what motivates her, as an entrepreneur. “We often get pictures of new-born babies and that moves us a lot. Even from the people who don’t succeed, we get really amazing feedback on the support that we offer. Our one mission is to help patients live their life while creating one.”

For more information, visit apricity.life.

 

 

 

 

Insight

IVFmicro raises £3.5m to boost IVF success

Published

on

IVFmicro has raised £3.5m to advance its microfluidic device designed to improve IVF success rates in routine clinic use.

The Leeds-based spinout from the University of Leeds, founded in 2024, aims to increase the quality and number of embryos in an IVF cycle.

IVF, or in vitro fertilisation, combines eggs and sperm in a lab before transferring embryos to the womb. A microfluidic device is a chip with tiny channels that move very small volumes of fluid.

The company says its device could raise the number of viable embryos available for transfer and the likelihood that an embryo will implant.

Currently, IVF leads to a successful pregnancy in about 30 per cent of cases for women under 35. A single cycle typically costs around £5,000 in the UK.

“My career has focused on understanding the reproductive biology of eggs and embryos, how they develop and, crucially, why things sometimes go wrong,” said IVFmicro co-founder and scientific director Helen Picton.

“At IVFmicro, we are harnessing years of research into reproductive biology to create a practical, accessible solution that can improve outcomes for patients undergoing fertility treatment. Our goal is to make IVF more effective, more predictable, and ultimately more hopeful for those striving to start a family.”

The investment was led by Northern Gritstone, with support from Innovate UK’s Investment Partnership Programme.

“IVFMicro is a brilliant example of the world-class innovation emerging from the Northern Arc’s universities, combining scientific excellence with a clear commercial vision to tackle the societal challenge of infertility,” said Northern Gritstone chief executive Duncan Johnson.

“Millions worldwide require fertility treatment, but new solutions are needed to overcome the high costs involved and low success rates. We are especially proud that IVFMicro’s journey has been supported through our NG Studios programme and our Innovation Services, which exist to help founders like Virginia and Helen turn pioneering research into real-world impact.”

Continue Reading

Features

University of Leeds IVF spinout raises £3.5m

Published

on

University of Leeds IVF spinout IVFmicro has raised £3.5m in pre-seed funding.

The investment is led by Northern Gritstone, with support from Innovate UK Investor Partnerships Programme, and will be used by IVFmicro for its next verification and validation phase, leading to trials on human embryos in fertility clinics.

Helen Picton is scientific director and co-founder of IVFmicro.

She said: “My career has focused on understanding the reproductive biology of eggs and embryos, how they develop and, crucially, why things sometimes go wrong.

“At IVFmicro, we are harnessing years of research into reproductive biology to create a practical, accessible solution that can improve outcomes for patients undergoing fertility treatment.

“Our goal is to make IVF more effective, more predictable, and ultimately more hopeful for those striving to start a family.”

Globally, 1 in 6 couples will face fertility issues, yet IVF success rates are suboptimal, with only 25-30 per cent succeeding in women under 35 years of age.

This is due in part to limitations of the embryo culture process, which typically involves repetitive handling, subjective selection of the best embryo, and the expense of highly skilled operators.

IVF is an expensive process, costing on average £5,000 for a patient in the UK for one cycle, accompanied by long NHS waiting lists that have selective criteria.

IVFmicro provides the first microfluidic device (a device for safely managing embryo culture and handling with very small amounts of nutrient-rich fluid) that can be used in any IVF treatment cycle.

This precision-engineered solution improves both the number of viable embryos available for transfer and the likelihood that an embryo will implant and result in a pregnancy.

IVFmicro provides a 10-15 per cent improvement in embryo quality and quantity, a significant leap that increases the potential to fall pregnant.

IVFmicro was founded in 2018 by Virginia Pensabene, Ph.D, and Helen Picton, Bsc, Ph.D., both professors at the University of Leeds.

Pensabene has published scientific advancements in microfluidics and brings her technical and scientific expertise to the product design.

Picton is a non-clinical expert in female reproductive biology and embryology, and has generated over £8m in research grant income.

IVFmicro recently took part in the NG Studios life sciences programme, which supports pre-seed life science businesses, and is delivered by accelerator KQ Labs, the Francis Crick Institute, and Northern Gritstone.

Virginia Pensabene, CEO and co-founder, IVFmicro, said: “As a biomedical engineer, I began exploring the potential of this technology in 2017, when Helen and I first met at the University of Leeds.

“From the start, our goal was to translate our research into a real solution for patients.

“Thanks to the combination of grant funding and Northern Gritstone’s support — both through investment and its innovation programmes — we have been able to grow our team in Leeds and take a major step toward bringing this precision-engineered IVF solution to market.”

Continue Reading

Fertility

Meta removes dozens of abortion advice and queer advocacy accounts

Published

on

Meta has removed or restricted dozens of accounts run by abortion providers, queer groups and reproductive health organisations in recent weeks.

Campaigners have called the takedowns one of the biggest waves of censorship on Meta’s platforms in years.

The actions began in October and targeted the Facebook, Instagram and WhatsApp accounts of more than 50 organisations worldwide, some serving tens of thousands of people.

Many were from Europe and the UK, with bans also affecting groups serving women in Asia, Latin America and the Middle East.

Repro Uncensored, an NGO tracking digital censorship against movements focused on gender, health and justice, said it had recorded 210 incidents of account removals and severe restrictions affecting these groups this year, compared with 81 last year.

Martha Dimitratou, executive director of Repro Uncensored, said: “Within this last year, especially since the new US presidency, we have seen a definite increase in accounts being taken down, not only in the US, but also worldwide as a ripple effect.

“This has been, to my knowledge, at least one of the biggest waves of censorship we are seeing.”

Meta denied any escalating trend of censorship and said its policies on abortion-related content had not changed.

“Every organisation and individual on our platforms is subject to the same set of rules, and any claims of enforcement based on group affiliation or advocacy are baseless,” it said in a statement.

Organisations affected include Netherlands-registered Women Help Women, a non-profit offering information about abortion to women worldwide that fields about 150,000 emails a year.

Kinga Jelinska, executive director of Women Help Women, said the ban could be “life-threatening”, pushing some women towards dangerous, less reliable information sources.

“It’s a very laconic explanation, a feeling of opacity,” Jelinska said. “They just removed it. That’s it. We don’t even know which post it was about.”

Meta said more than half of the accounts flagged by Repro Uncensored have been reinstated, including Women Help Women, which it said was taken down in error.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.